<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00576394</url>
  </required_header>
  <id_info>
    <org_study_id>H-25760</org_study_id>
    <nct_id>NCT00576394</nct_id>
  </id_info>
  <brief_title>Aggressive Versus Moderate Glycemic Control in Diabetic Coronary Bypass Patients</brief_title>
  <official_title>Impact of Aggressive Versus Moderate Glycemic Control on Clinical Outcomes Following Coronary Artery Bypass Graft Surgery in Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>American Heart Association</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      entGlycemic control has been found to improve clinical outcomes following Coronary Bypass
      Surgery. This study tests the hypothesis that obtaining tighter glycemic control(80-120mg/dl)
      as opposed to more moderate control (120-180mg/dl) will further improve outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      150 diabetic patients will be randomized to achieve aggressive glycemic control (80-120mg/dl)
      vs moderate control (120-180mg/dl) using intravenous insulin infusions beginning at
      anesthetic induction and continuing for 18 hours following surgery.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Hypoglycemia</measure>
    <time_frame>24 hours following surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>free fatty acid levels</measure>
    <time_frame>24 hours following surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>Glycemic Control</condition>
  <arm_group>
    <arm_group_label>1Moderate Glycemic Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive an insulin drip to keep blood glucose levels between 120-180mg/dl</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2Aggressive Glycemic Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive an insulin drip designed to maintain serum glucose between 80-120mg/dl</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Insulin drip</intervention_name>
    <description>IV insulin drip at 100units insulin in 100ml saline designed to keep blood glucose between 120-180mg/dl</description>
    <arm_group_label>1Moderate Glycemic Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>IV insulin drip to keep serum glucose between 80-120mg/dl.</description>
    <arm_group_label>2Aggressive Glycemic Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All diabetic patients undergoing Coronary Bypass Surgery

        Exclusion Criteria:

          -  Patients with hepatic and renal failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Lazar HL, McDonnell MM, Chipkin S, Fitzgerald C, Bliss C, Cabral H. Effects of aggressive versus moderate glycemic control on clinical outcomes in diabetic coronary artery bypass graft patients. Ann Surg. 2011 Sep;254(3):458-63; discussion 463-4. doi: 10.1097/SLA.0b013e31822c5d78.</citation>
    <PMID>21865944</PMID>
  </results_reference>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2007</study_first_submitted>
  <study_first_submitted_qc>December 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2007</study_first_posted>
  <last_update_submitted>June 22, 2015</last_update_submitted>
  <last_update_submitted_qc>June 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>American Heart Association</investigator_affiliation>
    <investigator_full_name>Harold L. Lazar MD</investigator_full_name>
    <investigator_title>Professor of Cardiothoracic Surgery</investigator_title>
  </responsible_party>
  <keyword>Glucose, Insulin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

